Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from https://aidsinfo.nih.gov/guidelines on 5/17/2020

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
Table 15b. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Dyslipidemia  (Last updated  April 14, 2020; last reviewed April 14, 2020)  (page 1 of 2)

<table>
<thead>
<tr>
<th>Adverse Effects</th>
<th>Associated ARVs</th>
<th>Onset/Clinical Manifestations</th>
<th>Estimated Frequency</th>
<th>Risk Factors</th>
<th>Prevention/Monitoring</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyslipidemia</td>
<td>PIs:</td>
<td>Onset: As early as 2 weeks to months after beginning therapy</td>
<td>Reported frequency varies with specific ARV regimen, duration of ART, and the specific laboratory parameters used to diagnose lipid abnormalities. 10% to 20% of young children receiving LPV/r will have lipid abnormalities. 40% to 75% of older children and adolescents with prolonged ART history will have lipid abnormalities. Higher abnormal fasting serum lipids have been observed in ART-naive adults who received EVG/c/FTC/TAF than in those who received EVG/c/FTC/TDF. Increase in serum lipids from baseline has also been noted in adolescents receiving EVG/c/FTC/TAF.</td>
<td>Advanced-stage HIV disease High-fat, high-cholesterol diet Lack of exercise Obesity Hypertension Smoking Family history of dyslipidemia or premature ASCVD Metabolic syndrome Fat maldistribution</td>
<td>Prevention: • Low-fat diet • Exercise • Smoking-prevention counseling • When possible, use ARVs associated with a lower prevalence of dyslipidemia. These include INSTIs and newer PIs (e.g., ATV, DRV). Monitoring* Adolescents and Adults: • Obtain FLP (TC, HDL-C, non-HDL-C, LDL-C, and TG) twice (&gt;2 weeks but ≤3 months apart, average these results) Monitor FLP every 6 months (for abnormal results) or every 12 months (for normal results). Children (Aged ≥2 Years) without Lipid Abnormalities or Additional Risk Factors: • Obtain nonfasting screening lipid profiles at entry into care and then every 6–12 months, depending on the results. • If TG or LDL-C is elevated or if a patient has additional risk factors, obtain FLP. Children with Lipid Abnormalities and/or Additional Risk Factors: • Obtain 12-hour FLP before initiating or changing therapy and every 6 months thereafter (more often if indicated). Children Receiving Lipid-Lowering Therapy with Statins or Fibrates: • Obtain 12-hour FLP, LFT, and CK at 4 weeks, 8 weeks, and 3 months after starting lipid therapy.</td>
<td>Assess all patients for additional ASCVD risk factors. Patients with HIV are considered to be at moderate risk of ASCVD. ARV regimen changes should be considered, especially when the patient is receiving older PIs (e.g., LPV/r) and/or RTV boosting. Switching to a PI-sparing regimen, a PI-based regimen with a more favorable lipid profile, or COBI boosting causes a decline in LDL-C or TG values. However, the lipid-lowering effect for LDL-C is less pronounced than with statin therapy. Refer patients to a lipid specialist early if LDL-C is ≥250 mg/dL or TG is ≥500 mg/dL. If LDL-C is ≥130 mg/dL but &lt;250 mg, or TG is ≥150 mg/dL but &lt;500 mg/dL, the following staged treatment approach is recommended by the NHLBI guidelines:* • Implement diet, nutrition, and lifestyle management for 6–9 months. Consult with a dietician if one is available. • If a 6-month to 9-month trial of lifestyle modification fails and the patient is aged ≥10 years, consider implementing lipid-lowering therapy after consulting a lipid specialist. • Statin therapy should be considered for patients with elevated LDL-C levels. NHLBI provides recommendations for statin therapy in patients with specific LDL-C levels and risk factors.*</td>
</tr>
</tbody>
</table>
Table 15b. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Dyslipidemia (Last updated April 14, 2020; last reviewed April 14, 2020) (page 2 of 2)

<table>
<thead>
<tr>
<th>Adverse Effects</th>
<th>Associated ARVs</th>
<th>Onset/Clinical Manifestations</th>
<th>Estimated Frequency Risk Factors</th>
<th>Prevention/Monitoring</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyslipidemia, continued</td>
<td></td>
<td></td>
<td>If there are minimal alterations in AST, ALT, and CK, monitor every 3–4 months during the first year and every 6 months thereafter (or as clinically indicated). Repeat FLP 4 weeks after increasing doses of antihyperlipidemic agents.</td>
<td></td>
<td>Drug therapy can be considered in cases of severe hypertriglyceridemia (TG ≥500 mg/dL). Fibrates (gemfibrozil and fenofibrate) and N-3 PUFAs derived from fish oils may be used. The long-term risks of lipid abnormalities in children who are receiving ART are unclear. However, persistent dyslipidemia in children may lead to premature ASCVD.</td>
</tr>
</tbody>
</table>

a Given the burden of collecting fasting blood samples, some practitioners routinely measure cholesterol and TG from nonfasting blood samples and follow up abnormal values with a test done in the fasted state.

b Refer to the NHLBI guidelines: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents.

Key: ALT = alanine aminotransferase; ART = antiretroviral therapy; ARV = antiretroviral; ASCVD = atherosclerotic cardiovascular disease; AST = aspartate aminotransferase; ATP = atazanavir; CK = creatine kinase; COBI = cobicistat; DRV = darunavir; DRV/r = darunavir/ritonavir; EFV = efavirenz; ETR = etravirine; EVG/c = elvitegravir/cobicistat; FLP = fasting lipid profile; FTC = emtricitabine; HDL-C = high-density lipoprotein cholesterol; INSTI = integrase strand transfer inhibitor; LDL-C = low-density lipoprotein cholesterol; LFT = liver function test; LPV/r = lopinavir/ritonavir; NHLBI = National Heart, Lung, and Blood Institute; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PUFA = polyunsaturated fatty acid; RPV = rilpivirine; RTV = ritonavir; TAF = tenofovir alafenamide; TC = total cholesterol; TDF = tenofovir disoproxil fumarate; TG = triglycerides

References


Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from [https://aidsinfo.nih.gov/guidelines](https://aidsinfo.nih.gov/guidelines) on 5/17/2020


Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection


**Table 15c. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects**  
(Last updated April 16, 2019; last reviewed April 14, 2020)  
(page 1 of 2)

<table>
<thead>
<tr>
<th>Adverse Effects</th>
<th>Associated ARVs</th>
<th>Onset/Clinical Manifestations</th>
<th>Estimated Frequency</th>
<th>Risk Factors</th>
<th>Prevention/ Monitoring</th>
<th>Management</th>
</tr>
</thead>
</table>
| Nausea/Vomiting | All ARV drugs, but most notably RTV-boosted PIs | **Onset:**  
• Early  
**Presentation:**  
• Nausea and emesis, both of which may be associated with anorexia and/or abdominal pain | Varies by ARV agent; generally <15% | Unknown | Instruct patient to take PIs with food.  
Monitor for weight loss and ARV adherence. | Reassure patient that these adverse effects generally improve over time (usually in 6–8 weeks).  
Consider switching to ARV drugs with smaller tablet sizes (see Appendix A, Table 2).  
Provide supportive care.  
In extreme or persistent cases, use antiemetics or switch to another ARV regimen. |
| Diarrhea | All ARV drugs, but most notably RTV-boosted PIs | **Onset:**  
• Early  
**Presentation:**  
• More frequent bowel movements and stools that are generally soft | Varies by ARV agent; generally <15% | Unknown | Monitor for weight loss and dehydration. | In prolonged or severe cases, exclude infectious or noninfectious (e.g., lactose intolerance) causes of diarrhea.  
Reassure patient that this adverse effect generally improves over time (usually in 6–8 weeks). Consider switching to another ARV regimen in persistent and severe cases.  
Treatment data in children are lacking; however, the following strategies may be useful when the ARV regimen cannot be changed:  
• Dietary modification  
• Using bulk-forming agents (e.g., psyllium)  
• Using antimotility agents (e.g., loperamide)  
• Using crofelemer, which is approved by the FDA to treat ART-associated diarrhea in adults aged ≥18 years; no pediatric data are available. |
### Pancreatitis

**Onset/Clinical Manifestations**
- Rare, but may occur with NRTIs or RTV-boosted PIs
- Onset: Any time, usually after months of therapy
- Presentation:
  - Emesis, abdominal pain, elevated amylase and lipase levels (asymptomatic hyperamylasemia or elevated lipase do not in and of themselves indicate pancreatitis)

**Estimated Frequency**
- <2% in a recent case series

**Risk Factors**
- Use of concomitant medications that are associated with pancreatitis (e.g., TMP-SMX, pentamidine, ribavirin)
- Hypertriglyceridemia
- Advanced HIV infection
- Previous episode of pancreatitis
- Alcohol use

**Prevention/ Monitoring**
- Measure serum amylase and lipase concentrations if persistent abdominal pain develops.
- If pancreatitis is associated with hypertriglyceridemia, consider using interventions to lower TG levels.

**Management**
- Discontinue offending agent and avoid reintroduction.
- Manage symptoms of acute episodes.

---

**Key:** ART = antiretroviral therapy; ARV = antiretroviral; FDA = Food and Drug Administration; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RTV = ritonavir; TG = triglyceride; TMP-SMX = trimethoprim sulfamethoxazole

**References**


